Major histocompatibility complex binding peptides: a target for therapeutic development.
Peptides that bind with high affinity to major histocompatibility complex molecules could represent useful tools in treating class II-associated autoimmune diseases such as rheumatoid arthritis, type 1 diabetes and multiple sclerosis. Although the concept has been validated in experiments with both purified receptor systems in vitro and cellular systems in vivo, many challenging problems need to be resolved before efficacious therapeutic agents are obtained.
Cytel, San Diego, California.
A
A
Sette
P
P
Wentworth
H M
HM
Grey
D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology; D005544:Forecasting; D006680:HLA Antigens / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy* / Q000276:immunology; D008285:Major Histocompatibility Complex; D010455:Peptides / Q000378:metabolism* / Q000627:therapeutic use
D006680:HLA Antigens; D010455:Peptides